CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-11-26
DOI
10.1038/s41467-022-34873-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adrenalitis and anasarca in idiopathic multicentric Castleman's disease
- (2021) Luke Y C Chen et al. LANCET
- Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease
- (2021) Yoshito Nishimura et al. AMERICAN JOURNAL OF HEMATOLOGY
- Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL‐6/JAK inhibition: A pediatric case series
- (2021) Hannah Lust et al. PEDIATRIC BLOOD & CANCER
- Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
- (2021) Sheila K. Pierson et al. Blood Advances
- Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma
- (2021) Tomohiro Aoki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increased mTOR activation in idiopathic multicentric Castleman disease
- (2020) Daniel J. Arenas et al. BLOOD
- Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
- (2020) David C. Fajgenbaum et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease
- (2019) David C. Fajgenbaum et al. JOURNAL OF CLINICAL INVESTIGATION
- Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
- (2018) Sheila K. Pierson et al. AMERICAN JOURNAL OF HEMATOLOGY
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
- (2018) Frits van Rhee et al. BLOOD
- Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data
- (2018) Deanna E. Morra et al. BRITISH JOURNAL OF HAEMATOLOGY
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
- (2018) David C. Fajgenbaum BLOOD
- Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan
- (2017) Shino Fujimoto et al. Modern Rheumatology
- CXCL13 is a plasma biomarker of germinal center activity
- (2016) Colin Havenar-Daughton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CXCL13 antibody for the treatment of autoimmune disorders
- (2015) Ekaterina Klimatcheva et al. BMC IMMUNOLOGY
- Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: Characterization of differential expression patterns in cerebral vasospasm
- (2014) Brian P. Walcott et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'
- (2014) Stinne Ravn Greisen et al. ARTHRITIS RESEARCH & THERAPY
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started